Activation of PPAR‐γ by glitazones can re‐sensitize imatinib‐resistant CML to treatment by downregulating STAT5 expression and its downstream targets HIF2a and CITED2, two key guardians involved with quiescence and stemness of CML leukaemia stem cells. Here, PPARG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.